Poulikos I. Poulikakos
Title
Cited by
Cited by
Year
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
PI Poulikakos, C Zhang, G Bollag, KM Shokat, N Rosen
Nature 464 (7287), 427-430, 2010
16882010
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E)
PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ...
Nature 480 (7377), 387-390, 2011
13832011
Targeting RAS–ERK signalling in cancer: promises and challenges
AA Samatar, PI Poulikakos
Nature reviews Drug discovery 13 (12), 928-942, 2014
7812014
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
EW Joseph, CA Pratilas, PI Poulikakos, M Tadi, W Wang, BS Taylor, ...
Proceedings of the National Academy of Sciences 107 (33), 14903-14908, 2010
4562010
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
P Lito, CA Pratilas, EW Joseph, M Tadi, E Halilovic, M Zubrowski, ...
Cancer cell 22 (5), 668-682, 2012
4462012
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ...
Cancer discovery 1 (3), 248-259, 2011
4222011
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis
R Chakraborty, OA Hampton, X Shen, SJ Simko, A Shih, H Abhyankar, ...
Blood, The Journal of the American Society of Hematology 124 (19), 3007-3015, 2014
3042014
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model
S Mabuchi, DA Altomare, M Cheung, L Zhang, PI Poulikakos, HH Hensley, ...
Clinical cancer research 13 (14), 4261-4270, 2007
2772007
BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition
Z Yao, NM Torres, A Tao, Y Gao, L Luo, Q Li, E de Stanchina, ...
Cancer cell 28 (3), 370-383, 2015
2692015
Mutant BRAF melanomas—dependence and resistance
PI Poulikakos, N Rosen
Cancer cell 19 (1), 11-15, 2011
2542011
Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells
HQ Wang, DA Altomare, KL Skele, PI Poulikakos, FP Kuhajda, ...
Oncogene 24 (22), 3574-3582, 2005
2162005
New perspectives for targeting RAF kinase in human cancer
Z Karoulia, E Gavathiotis, PI Poulikakos
Nature Reviews Cancer 17 (11), 676-691, 2017
1802017
Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK
PI Poulikakos, GH Xiao, R Gallagher, S Jablonski, SC Jhanwar, JR Testa
Oncogene 25 (44), 5960-5968, 2006
1742006
Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity
N Ishii, N Harada, EW Joseph, K Ohara, T Miura, H Sakamoto, Y Matsuda, ...
Cancer research 73 (13), 4050-4060, 2013
1212013
Human follicle-stimulating hormone (FSH) receptor interacts with the adaptor protein APPL1 in HEK 293 cells: potential involvement of the PI3K pathway in FSH signaling
CA Nechamen, RM Thomas, BD Cohen, G Acevedo, PI Poulikakos, ...
Biology of reproduction 71 (2), 629-636, 2004
1212004
Resistance to MEK inhibitors: should we co-target upstream?
PI Poulikakos, DB Solit
Science signaling 4 (166), pe16-pe16, 2011
1172011
An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling
Z Karoulia, Y Wu, TA Ahmed, Q Xin, J Bollard, C Krepler, X Wu, C Zhang, ...
Cancer cell 30 (3), 485-498, 2016
1002016
Growth inhibition and induction of apoptosis in mesothelioma cells by selenium and dependence on selenoprotein SEP15 genotype
S Apostolou, JO Klein, Y Mitsuuchi, JN Shetler, PI Poulikakos, ...
Oncogene 23 (29), 5032-5040, 2004
992004
Personalized preclinical trials in BRAF inhibitor–resistant patient-derived xenograft models identify second-line combination therapies
C Krepler, M Xiao, K Sproesser, PA Brafford, B Shannan, M Beqiri, Q Liu, ...
Clinical Cancer Research 22 (7), 1592-1602, 2016
952016
Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis
R Chakraborty, TM Burke, OA Hampton, DJ Zinn, KPH Lim, H Abhyankar, ...
Blood, The Journal of the American Society of Hematology 128 (21), 2533-2537, 2016
892016
The system can't perform the operation now. Try again later.
Articles 1–20